Title : Camostat-polysaccharide dual-action nasal spray for mucosal barrier-driven prevention of viral infections
Abstract:
Antiviral activity was demonstrated in human nasal epithelial cells and a mouse influenza model. The formulation inhibited viral entry in vitro and suppressed TMPRSS2 expression in vivo, a key factor for viral penetration. Cytotoxicity tests confirmed no toxicity, following ISO 10993-5. To evaluate mucosal adhesion, a fluorescently labeled the formulation was intranasally administered in mice. Compared to the control group treated with a non-viscous fluorescent dye, the formulation-treated group retained over 80% of initial fluorescence for 8 hours, and more than 50% even after 24 hours. These findings demonstrate the formulation’s excellent adhesion, sustained retention in the nasal cavity, and potential as a protective mucosal barrier. The camostat–polysaccharide nasal spray blocks viral entry at the nasal mucosa, preventing infection at the source. Even low virus exposure can cause severe illness in vulnerable individuals. With high muco-adhesiveness and TMPRSS2 suppression, the camostat–polysaccharide nasal spray prevents influenza replication. These findings suggest that the camostat–polysaccharide dual-action nasal spray, currently under development, holds promise as a non-invasive, first-line barrier to prevent the initial infection and replication of respiratory viruses.
